CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 196 enrolled
Drug / intervention
Opti-Free® PureMoist® MPDS +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01684046
NCT01684046N/ACompleted
CompareCT.gov

Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2

Alcon Research·interventional·Posted Sep 12, 2012·Updated Apr 29, 2014

In Brief

A clinical study evaluating Opti-Free® PureMoist® MPDS, RevitaLens MPDS, and 1 other intervention for Myopia and 2 related conditions. Completed, enrolled 196 participants.

Detailed Summary

The purpose of this study was to evaluate the performance of Opti-Free® PureMoist® Multi-purpose Disinfecting Solution (MPDS) compared to AMO RevitaLens OcuTec® MPDS (US brand name)/COMPLETE RevitaLens (Europe brand name) in silicone hydrogel contact lens wearers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia, Hyperopia, Contact Lens Comfort
Countries--
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 12, 2012
Enrollment StartNov 1, 2012
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.8 years ago

Interventions

Opti-Free® PureMoist® MPDSdevice

RevitaLens MPDSdevice

Habitual Contact Lensesdevice

Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.